In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Eyenovia (EYEN), with a price target of $6.00. The company’s shares closed last Tuesday at $3.43.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 41.4% and a 38.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Eyenovia has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
See today’s analyst top recommended stocks >>
Based on Eyenovia’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.02 million. In comparison, last year the company had a GAAP net loss of $5.33 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The company was founded on March 12, 2014 and is headquartered in New York, NY.
Read More on EYEN:
